Navigation Links
Vanda Pharmaceuticals, Inc. Sued by Investor
Date:7/7/2013

SAN DIEGO and WASHINGTON, July 3, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP announce that a shareholder of Vanda Pharmaceuticals, Inc. (NasdaqGM: VNDA) securities has filed a complaint in the U.S. District Court for the District of Columbia against the company and certain of its officers and directors.  The complaint alleges that defendants violated the Securities Exchange Act of 1934 between December 18, 2012 and June 18, 2013 (the "Class Period").

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Vanda is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  The company's product portfolio includes tasimelteon, which is currently in clinical development for "Non-24," a neurological sleep disorder that affects proportionately more totally blind individuals than sighted.

Vanda Is Accused of Making False and Misleading Statements Regarding Results of Its Clinical Trial for Tasimelteon

Throughout the Class Period, defendants made false and/or misleading statements and failed to disclose material adverse facts about the results of the clinical trial for tasimelteon.  Specifically, defendants made false and/or misleading statements and failed to disclose that: (i) the company made multiple changes in the primary endpoint over the course of the trials; (ii) the company eliminated nighttime total sleep as the primary endpoint in its studies as there was no discernible difference in efficacy and safety in nighttime total sleep between those patients deemed to have Non-24 and those patients with a normal sleep cycle; and (iii) the company made a change in a new primary endpoint just one mo
'/>"/>

SOURCE Robbins Arroyo LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
2. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
3. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
4. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
5. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
6. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
7. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
8. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
9. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
10. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
11. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- Levi & Korsinsky announces it has commenced an ... concerning possible violations of federal securities laws. The investigation ... with its study of the drug OHR-102. To obtain ... Joseph E. Levi, Esq. either via email ... 363-7500, toll-free: (877) 363-5972. Levi & Korsinsky ...
(Date:3/27/2015)... , March 27, 2015  Holographic Optical Technologies of ... field of holographic medical imaging, is entering the world ... campaign. Launching on April 20 th , 2015, the ... Pro. The 8-inch and 22-inch displays will allow consumers ... the first time. In addition to the two displays, ...
(Date:3/27/2015)... -- A new report from Kalorama Information says that other ... Chile , Colombia and ... firms.  The healthcare research firm said that while ... Latin American continent with a population of over 200 million ... the country,s regional economic clout does not necessarily ensure its ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
... Calif., Feb. 2 InterMune, Inc.,(Nasdaq: ITMN ... its Phase 3,CAPACITY program of pirfenidone in idiopathic pulmonary ... InterMune will conduct a conference,call and webcast, with ... at 8:00 a.m. EST (5:00 a.m. PST) on Tuesday,February ...
... ability of human-animal hybrids to generate stem cells ... (OTC Pink Sheets: ACTC) and its collaborators reported today ... extensively reprogram adult human cells. The research, which appears ... and Stem Cells (Editor-in-Chief: Sir Ian Wilmut; published ...
Cached Medicine Technology:InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3 2Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs 2Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs 3Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs 4Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs 5
(Date:3/27/2015)... 27, 2015 Ticket Down is a reputable source ... 2015. After a phenomenal and highly successful live tour last ... going out on tour again in 2015 and they will be ... on April 29th in New York City at the cozy Beacon ... Theatre on May 10th. , Fans of the hit show can ...
(Date:3/27/2015)... 27, 2015 According to a recently ... the plate and screw market in Europe is in ... plate and screw segment. Price decreases are being seen ... almost 50% of the total European trauma device market, ... total market value, year after year. , “Such ...
(Date:3/27/2015)... March 27, 2015 The report “CountryFocus: ... essential source of information on and analysis of the ... population of the US in 2013 amounted to 316.1 ... (CAGR) of 0.8% from 2008. The country’s increasingly elderly ... diseases will help to boost the growth of the ...
(Date:3/27/2015)... Diego, CA (PRWEB) March 27, 2015 ... launch its Protect Our Children (POC) NOW! vitamin D ... the Medical University of South Carolina (MUSC), and will ... will be available at no cost to a minimum ... gestation who live within these two service areas. The ...
(Date:3/27/2015)... 27, 2015 Trail mix is the perfect, ... on weekend hikes and during the game! It’s portable, lightweight ... is proud to introduce a new line of specialty trail ... rich and flavorful selections packed with nutritious, 100% all natural ... and grains that add protein and fiber to your diet ...
Breaking Medicine News(10 mins):Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2
... study in the September 27 issue of JAMA says that ... the risk of reinfections.// Trachoma is an infectious disease where ... reported that 15 percent of all blindness was caused by ... cataract., ,At that time, the WHO estimated that 146 ...
... a condom that plays music during sex, Korrespondent magazine ... control device as a novelty, and as an aid ... miniature loudspeaker and motion sensor implanted in the condom's ... sex. ,The condom's main limitation is primitive ...
... for infecting cornea cells that may also explain how it ... at the University of Illinois at Chicago College of Medicine. ... of the Journal of Cell Biology. ,Both strains ... cold sores on the mouth, and HSV-2, genital herpes -- ...
... the Johns Hopkins University and other institutions have developed ... Lynch syndrome// , which predisposes families to develop colorectal ... individual’s detailed family history of colorectal and endometrial cancer, ... themselves—in the form of tumors. It can assess a ...
... ?4 million cash boost to fight the spread of the deadly ... towards stemming Scotland's high rates of the infection as well as ... been estimated that about 20,000 people have been infected with Hepatitis ... among Scotland's drug users - in NHS Greater Glasgow and Clyde. ...
... proposed by the FDA for the anti-angiogenic colorectal-cancer drug ... posterior leukoencephalopathy syndrome in its warning.// ,Genentech, ... has been reported or confirmed in less than 0.1% ... ,The Adverse Reactions and Dosage and Administration ...
Cached Medicine News:Health News:Blindness And Trachoma 2Health News:Herpes Infects Cornea, Evades Immune Cells 2Health News:Model Predicts Colon Cancer Inheritable Genetic Defects 2Health News:Scotland’s Fight against Hepatitis C Boosted by ? 2Health News:Warning on Avastin Updated 2
Lytec Medical 2004 practice management software is designed to help you more effectively manage your accounts receivable as well as track authorizations and inventory. Lytec Medical XE provides outst...
PremierEdge™ Stab Knives - 30°....
DCR Set, Angled....
... Leica CM3050 S Cryostat Family ... excellent safety standards for practically ... The Leica CM3050 S is ... all cryosectioning research applications and ...
Medicine Products: